@article{f1da0865fa8d4fd4b7d0d2cb62656bce,
title = "Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression",
abstract = "Noncoding RNAs (ncRNAs) are emerging as key molecules in human cancer, with the potential to serve as novel markers of disease and to reveal uncharacterized aspects of tumor biology. Here we discover 121 unannotated prostate cancer-associated ncRNA transcripts (PCATs) by ab initio assembly of high-throughput sequencing of polyA + RNA (RNA-Seq) from a cohort of 102 prostate tissues and cells lines. We characterized one ncRNA, PCAT-1, as a prostate-specific regulator of cell proliferation and show that it is a target of the Polycomb Repressive Complex 2 (PRC2). We further found that patterns of PCAT-1 and PRC2 expression stratified patient tissues into molecular subtypes distinguished by expression signatures of PCAT-1-repressed target genes. Taken together, our findings suggest that PCAT-1 is a transcriptional repressor implicated in a subset of prostate cancer patients. These findings establish the utility of RNA-Seq to identify disease-associated ncRNAs that may improve the stratification of cancer subtypes.",
author = "Prensner, {John R.} and Iyer, {Matthew K.} and Balbin, {O. Alejandro} and Dhanasekaran, {Saravana M.} and Qi Cao and Brenner, {J. Chad} and Bharathi Laxman and Asangani, {Irfan A.} and Grasso, {Catherine S.} and Kominsky, {Hal D.} and Xuhong Cao and Xiaojun Jing and Xiaoju Wang and Javed Siddiqui and Wei, {John T.} and Daniel Robinson and Iyer, {Hari K.} and Nallasivam Palanisamy and Maher, {Christopher A.} and Chinnaiyan, {Arul M.}",
note = "Funding Information: We thank K. Ramnarayanan and R. Morey for technical assistance with next generation sequencing. We thank R.J. Lonigro, S. Kaylana-Sundaram, T. Barrette, and M. Quist for help with sequencing data analysis, and R. Mehra, B. Han and K. Suleman for prostate tissue specimens. We thank C. Trapnell and G. Pertea for assistance with computational analyses. We thank S. Tomlins, Y.-M. Wu, S. Roychowdhury and members of the Chinnaiyan laboratory for advice and discussions. We thank R. Beroukhim for guidance. This work was supported in part by the US National Institutes of Health (NIH) Prostate Specialized Program of Research Excellence grant P50CA69568, the Early Detection Research Network grant UO1 CA111275 (to A.M.C.), the NIH R01CA132874-01A1 (to A.M.C.), the Department of Defense grant W81XWH-10-0652 and W81XWH-11-1-0337 (to A.M.C.) and the National Center for Functional Genomics supported by the Department of Defense (to A.M.C.). A.M.C. is supported by the Doris Duke Charitable Foundation Clinical Scientist Award, a Burroughs Wellcome Foundation Award in Clinical Translational Research and the Prostate Cancer Foundation. A.M.C. is an American Cancer Society Research Professor. N.P. was supported by a University of Michigan Prostate SPORE Career Development Award. C.A.M. was supported by the American Association of Cancer Research Amgen Fellowship in Clinical/Translational Research, the Canary Foundation and American Cancer Society Early Detection Postdoctoral Fellowship, and a Prostate Cancer Foundation Young Investigator Award. Q.C. was supported by a Department of Defense Postdoctoral Fellowship grant PC094725. J.R.P. was supported by the NIH Cancer Biology Training grant CA009676-18 and the Department of Defense Predoctoral Fellowship W81XWH-10-1-0551. M.K.I. was supported by the Department of Defense Predoctoral Fellowship W81XWH-11-1-0136. J.R.P. and M.K.I. are Fellows of the University of Michigan Medical Scientist Training Program.",
year = "2011",
month = aug,
doi = "10.1038/nbt.1914",
language = "English (US)",
volume = "29",
pages = "742--749",
journal = "Nature Biotechnology",
issn = "1087-0156",
publisher = "Nature Publishing Group",
number = "8",
}